News

The company has also notified the owner of the Reference Listed Drug of its filing. In November, Endo Pharmaceuticals Solutions, Bayer Intellectual Property and Bayer Pharma filed suit

Chimerasome is based on a single protein that can be assembled to form a spherical protein nanocage encapsulating drugs or nucleic acid therapeutics. It can be decorated with

Acromegaly is a syndrome that results when the anterior pituitary gland produces excess growth hormone (GH) after epiphyseal plate closure at puberty. Novartis Oncology president Bruno Strigini said:

Duaklir is a fixed-dose combination of Eklira (aclidinium bromide), a long-acting muscarinic-antagonist (LAMA), with the long-acting beta-agonist (LABA) formoterol. Administered by the Genuair dry powder inhaler device, the

The new vaccine uses the ImuXen Technology based on the concept of simultaneous delivery of multiple active pharmaceutical ingredients (APIs) as antigens within the same liposome. The trial

The trial was designed to evaluate the safety, tolerability and pharmacokinetics of low doses of ITI-007 in these patients. According to the company, secondary endpoints of the trial

ZS003 was a Phase 3, 753 patient, multicenter, randomized, double-blind, placebo-controlled trial that assessed the safety and efficacy of ZS-9 (sodium zirconium cyclosilicate) in treating patients with hyperkalemia,

This marks the first launch of Fycompa in the Asia region. Fycompa is a highly selective, noncompetitive AMPA receptor antagonist discovered and developed by Eisai. With epileptic seizures

The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and